Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

European Neuropsychopharmacology - Tập 25 - Trang 483-492 - 2015
José Carlos Bouso1,2, Fernanda Palhano-Fontes3, Antoni Rodríguez-Fornells4,5, Sidarta Ribeiro3, Rafael Sanches6, José Alexandre S. Crippa6, Jaime E.C. Hallak6, Draulio B. de Araujo3, Jordi Riba1,7,8
1Human Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), C/Sant Antoni María Claret, 167, 08025 Barcelona, Spain
2International Center for Ethnobotanical Education, Research & Service, Barcelona, Spain
3Brain Institute/Hospital Universitario Onofre Lopes, Federal University of Rio Grande do Norte, Natal, Brazil
4Cognition and Brain Plasticity Group, IDIBELL (Bellvitge Biomedical Research Institute), L’Hospitalet de Llobregat, Barcelona 08097, Spain
5Department of Basic Psychology, University of Barcelona, Barcelona 08035, Spain
6Neuroscience and Behaviour Department, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
7Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
8Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain

Tài liệu tham khảo

Blacker, 1968, Chronic users of LSD: the “acidheads”, Am. J. Psychiatry, 125, 97, 10.1176/ajp.125.3.341

Bouso, 2013, Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users, Psychopharmacology (Berl.), 230, 415, 10.1007/s00213-013-3167-9

Bouso, 2012, Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study, PloS One, 7, e42421, 10.1371/journal.pone.0042421

Calhoun, 2011, Exploring the psychosis functional connectome: aberrant intrinsic networks in schizophrenia and bipolar disorder, Front. Psychiatry, 2, 75

Carhart-Harris, 2012, Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin, Proc. Natl. Acad. Sci. U.S.A., 109, 2138, 10.1073/pnas.1119598109

Cavanna, 2006, The precuneus: a review of its functional anatomy and behavioural correlates, Brain, 129, 564, 10.1093/brain/awl004

Cloninger, 1993, A psychobiological model of temperament and character, Arch. Gen. Psychiatry, 50, 975, 10.1001/archpsyc.1993.01820240059008

DelSer, 1997, Estimation of premorbid intelligence in Spanish people with the Word Accentuation Test and its application to the diagnosis of dementia, Brain Cogn., 33, 343, 10.1006/brcg.1997.0877

Derogatis, 1994

DeSteno, 2008, Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task, Neuroscience, 152, 417, 10.1016/j.neuroscience.2008.01.012

Destrieux, 1998, Variability of the human brain studied on the flattened cortical surface, Soc. Neurosci. Abstr., 24, 1164

Fábregas, 2010, Assessment of addiction severity among ritual users of ayahuasca, Drug Alcohol Depend., 111, 257, 10.1016/j.drugalcdep.2010.03.024

Fischl, 2004, Automatically parcellating the human cerebral cortex, Cereb. Cortex (New York, NY), 1991, 11

Fox, 2005, The human brain is intrinsically organized into dynamic, anticorrelated functional networks, Proc. Natl. Acad. Sci. U.S.A., 102, 9673, 10.1073/pnas.0504136102

Frankel, 2002, The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain, Brain Res., 958, 251, 10.1016/S0006-8993(02)03548-5

Gewirtz, 2002, Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors, Pharmacol. Biochem. Behav., 73, 317, 10.1016/S0091-3057(02)00844-4

González-Maeso, 2009, Agonist-trafficking and hallucinogens, Curr. Med. Chem., 16, 1017, 10.2174/092986709787581851

González-Maeso, 2007, Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior, Neuron, 53, 439, 10.1016/j.neuron.2007.01.008

Griffiths, 2011, Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects, Psychopharmacology (Berl.), 218, 649, 10.1007/s00213-011-2358-5

Grob, 2011, Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer, Arch. Gen. Psychiatry, 68, 71, 10.1001/archgenpsychiatry.2010.116

Grob, 1996, Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil, J. Nerv. Ment. Dis., 184, 86, 10.1097/00005053-199602000-00004

Heaton, 2001

Horn, 2013, The structural-functional connectome and the default mode network of the human brain, NeuroImage.

Jones, 2001, A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories, Nat. Neurosci., 4, 289, 10.1038/85138

Kircher, 1958, Age differences in short-term retention of rapidly changing information, J. Exp. Psychol., 55, 352, 10.1037/h0043688

MacLean, 2011, Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness, J. Psychopharmacol. (Oxford, England), 25, 1453, 10.1177/0269881111420188

Marona-Lewicka, 2011, An animal model of schizophrenia based on chronic LSD administration: old idea, new results, Neuropharmacology, 61, 503, 10.1016/j.neuropharm.2011.02.006

McCrae, 2009, The five-factor model of personality traits: consensus and controversy

Moreno, 2013, Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice, Neurosci. Lett., 536, 69, 10.1016/j.neulet.2012.12.053

Muthukumaraswamy, 2013, Broadband cortical desynchronization underlies the human psychedelic state, J. Neurosci., 33, 15171, 10.1523/JNEUROSCI.2063-13.2013

Nelson, 1978, Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test, Cortex, 14, 234, 10.1016/S0010-9452(78)80049-5

O’Donovan, 1999, The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience, Trends Neurosci., 22, 167, 10.1016/S0166-2236(98)01343-5

Pahnke, 1969, Psychedelic drugs and mystical experience, Int. Psychiatry Clin., 5, 149

Poirier, 2008, Distinct functions of egr gene family members in cognitive processes, Front. Neurosci., 2, 47, 10.3389/neuro.01.002.2008

Raichle, 2011, The restless brain, Brain Connect., 1, 3, 10.1089/brain.2011.0019

Raichle, 2001, A default mode of brain function, Proc. Natl. Acad. Sci. U.S.A., 98, 676, 10.1073/pnas.98.2.676

Riba, 2004, Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography, Neuropsychobiology, 50, 89, 10.1159/000077946

Riba, 2001, Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers., Psychopharmacology (Berl.), 154, 85, 10.1007/s002130000606

Riba, 2006, Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant, Psychopharmacology (Berl.), 186, 93, 10.1007/s00213-006-0358-7

Savage, 1966, The effects of psychedelic (LSD) therapy on values, personality, and behavior, Int. J. Neuropsychiatry, 2, 241

Schultes, 1979

Soulé, 2006, Brain-derived neurotrophic factor and control of synaptic consolidation in the adult brain, Biochem. Soc. Trans., 34, 600, 10.1042/BST0340600

Spreng, 2012, The fallacy of a “task-negative” network, Front. Psychol., 3, 145, 10.3389/fpsyg.2012.00145

Strassman, 1994, Dose–response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale, Arch. Gen. Psychiatry, 51, 98, 10.1001/archpsyc.1994.03950020022002

Tupper, 2008, The globalization of ayahuasca: harm reduction or benefit maximization?, Int. J. Drug Policy, 19, 297, 10.1016/j.drugpo.2006.11.001

Vollenweider, 1997, Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis, Neuropsychopharmacology, 16, 357, 10.1016/S0893-133X(96)00246-1

Wechsler, 1981

Zimmermann, 1994

Thông tin
Thông tin xuất bản

European Neuropsychopharmacology

Tập 25

483-492

Thông tin tác giả